Methods of treating endometriosis and other non-cancer gynecological disorders with hemp extract

Patent metadata

Field	Value
Publication number	US-11654172-B2
Application number	US-202218050023-A
Country	US
Kind code	B2
Filing date	Oct 26, 2022
Priority date	Oct 26, 2021
Publication date	May 23, 2023
Grant date	May 23, 2023

Abstract

A method for treating a noncancerous gynecological disorder comprising: administering to a patient and effective amount of composition comprising a cannabis extract comprising cannabidiol (CBD), wherein the composition is preferably administered in a mucosal form, such as intravaginally.

First claim

What is claimed is:

1. A method for treating a noncancerous gynecological disorder (NCGD) selected from the group consisting of: ovarian endometrioma, a deep endometriosis, dysmenorrhea, and fibroids; the method comprising administering to a patient an effective amount of a composition comprising a cannabis extract (CE) comprising cannabidiol (CBD), wherein the composition has a pH of between 3.5 and 6.

2. The method of claim 1 wherein the CE comprises between 50% and 99.9% by weight of CBD.

3. The method of claim 1 wherein the CE is selected from the group consisting of: a full spectrum hemp extract (FSHE), a broad spectrum hemp extract (BSHE), and a cannabidiol (CBD) isolate.

4. The method of claim 1 wherein the CE is administered via an oral form, oral mucosal form, intravaginal form, nasal mucosal form, rectal form, injectable form, or combinations thereof.

5. The method of claim 1 wherein the effective amount of the CE comprises between 10 mg and 4,250 mg of cannabidiol (CBD) per day.

6. The method of claim 1 wherein the CE further comprises a cannabidiolic acid (CBDA) at a concentration of between 0.1% and 10%.

7. The method of claim 1 wherein the CE is a broad spectrum hemp extract (BSHE) or a full spectrum hemp extract (FSHE) and wherein each of the BSHE or FSHE comprises 50% to 99% by weight of cannabidiol (CBD) and at least one other cannabinoid at a concentration of 0.1% to 10% wherein the at least one other cannabinoid is selected from the group consisting of: Δ-9-tetrahydrocannabinol (Δ 9 -THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), Δ-8-tetrahydrocannabinol (Δ 8 -THC), cannabichromene (CBC), cannabichromene acid (CBCA), cannabigerol (CBG), cannabigerol acid (CBGA), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabinol (CBN), cannabicyclol (CBL), and combinations thereof.

8. The method of claim 1 wherein the CE comprises cannabidiol (CBD) at a concentration of between 60% and 99% and at least one other cannabinoid at a concentration of 0.1% to 10% wherein the at least one other cannabinoid is selected from the group consisting of: Δ-9-tetrahydrocannabinol (Δ 9 -THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), Δ-8-tetrahydrocannabinol (Δ 8 -THC), cannabichromene (CBC), cannabichromene acid (CBCA), cannabigerol (CBG), cannabigerol acid (CBGA), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabinol (CBN), cannabicyclol (CBL), and combinations thereof, and wherein the CE comprises a total concentration of cannabinoids of between 65% and 99%.

9. The method of claim 1 wherein the composition comprises at least one additional compound selected from the group consisting of: a terpene, a polyphenol, an essential fatty acid, a phytonutrient, and combinations thereof; and wherein the at least one additional compound makes up between 0.1% and 50% by weight of the composition.

10. The method of claim 1 wherein the composition comprises an oil or a fat as a carrier.

11. The method of claim 1 wherein the effective amount of the composition is an amount sufficient to reach an effective therapeutic level of cannabidiol (CBD) as measured through systemic plasma levels.

12. The method of claim 9 wherein:
a. the terpene is selected from the group consisting of: β-myrcene, β-caryophyllene, linalool, α-pinene, citral, D -limonene, eucalyptol, and combinations thereof;
b. wherein the polyphenol is selected from the group consisting of: catechins, quercetin, cannflavin A/B/C, rutin, chlorogenic acid, and combinations thereof;
c. wherein the essential fatty acid is selected from the group consisting of: an omega 3, an omega 6, an omega 9, and combinations thereof, and
d. wherein the phytonutrient is selected from the group consisting of: a tocopherol, a sterol, carotene, an aliphatic alcohol, a mineral, and combinations thereof.

Assignees

• Ecofibre Ltd
• Univ Newcastle

Inventors

• Capano Alexandra M
• Tanwar Pradeep Singh
• Nance Alex

Classifications

• A61K36/185 Primary

  Magnoliopsida (dicotyledons) · CPC title

• A61K36/3482 Primary

  Cannabis · CPC title

• A61K31/658

  o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol · CPC title

• A61K31/105

  Persulfides (thiuram disulfides A61K31/145; thiosulfonic acids A61K31/185) · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title